The results, described by an expert as “very interesting” and a “a bit surprising," focused on the impact of autoimmune antibodies on anti–PD-1 therapy.
Christina Bennett, MS
Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.
Investigators evaluated whether patients with pancreatic ductal adenocarcinoma benefit from adjuvant therapy after surgery if the tumor is smaller than 1 cm.
A large pooled analysis of individuals with advanced esophageal cancer showed men and women have different side effects to chemotherapy.
A recent study in JAMA Oncology examined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic.